We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





New Molecular Diagnostic Platform Developed Using Gold Nanoparticles Shortens COVID-19 Diagnosis Time

By LabMedica International staff writers
Posted on 24 Jan 2022
Print article
Illustration
Illustration

Researchers have used gold nanoparticles to develop a new molecular diagnostic platform that considerably reduces the time required for COVID-19 detection.

The novel nanotechnology-based platform introduced by researchers at the Chung-Ang University (Seoul, South Korea) could also create a paradigm shift in the field of molecular diagnostics, revolutionizing how we detect infectious diseases and tackle future epidemics.

Early COVID-19 detection and isolation are key for controlling disease transmission and protecting vulnerable populations. The current standard for COVID-19 diagnosis is reverse transcriptase-polymerase chain reaction (RT-PCR), a technique in which viral genes are detected after they undergo multiples cycles of amplification. However, this technique is time-consuming, creating a testing backlog across diagnostic centers and leading to delayed diagnoses. The new nanotechnology-based platform can shorten the time required for COVID-19 diagnosis. Their surface-enhanced Raman scattering (SERS)-PCR detection platform - prepared using gold nanoparticles (AuNPs) in the cavities of Au 'nanodimple' substrates (AuNDSs) - can detect viral genes after only eight cycles of amplification. That is almost one-third of the number required with conventional RT-PCR.

The team had earlier developed a novel detection platform in which high-sensitivity SERS signals are produced by AuNPs uniformly arranged in the cavities of AuNDSs through a technique called DNA hybridization. Based on this previous discovery, the researchers developed the novel SERS-PCR platform for COVID-19 diagnosis. The newly developed SERS-PCR assay uses SERS signals to detect "bridge DNA" - small DNA probes that slowly break down in the presence of target viral genes. Therefore, in samples from patients positive for COVID-19, the concentration of bridge DNA (and therefore the SERS signal) continuously decreases with progressive PCR cycles. In contrast, when SARS-CoV-2 is absent, the SERS signal remains unchanged.

The team tested the effectiveness of their system using two representative target markers of SARS-CoV-2, namely, the envelope protein (E) and RNA-dependent RNA polymerase (RdRp) genes of SARS-CoV-2. While 25 cycles were required for RT-PCR-based detection, the AuNDS-based SERS-PCR platform required only eight cycles, considerably reducing the testing duration. Thus, SERS-PCR could be an important tool in the arsenal against the COVID-19 pandemic as well as revolutionize infectious diseases are detected and future epidemics are tackled.

"Conventional RT-PCR is based on the detection of fluorescence signals, so 3–4 hours are required to detect SARS-CoV-2. This speed is not enough considering how rapidly COVID-19 spreads. We wanted to find a way to cut this time at least by half," said Prof. Jaebum Choo, explaining the motivation behind the study. "Although our results are preliminary, they provide an important proof-of-concept for the validity of SERS-PCR as a diagnostic technique. Our AuNDS-based SERS-PCR technique is a promising new molecular diagnostic platform that can considerably shorten the time required for gene detection compared to conventional RT-PCR techniques. This model can be further expanded by incorporating an automatic sampler to develop a next-generation molecular diagnostic system."

Related Links:
Chung-Ang University 

Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Creatine Kinase-MB Assay
CK-MB Test
New
Total Thyroxine Assay
Total Thyroxine CLIA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.